Seoul, South Korea · Founded 2021 · Privately Held (backing)
Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. Illimis Therapeutics is based in Seoul, South Korea and was founded in 2021. It has raised $64.3 million.
Last price · $/share
—
Implied valuation
—
Total raised
$64.3M
Last round
—
Cap table — not yet on record
Illimis Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Illimis Therapeutics with a free account
·The complete investor list: 27 names
·Watch Illimis Therapeutics: the Monday email on marks, rounds and moves
